Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Eli Lilly and Company ... approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity.

This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed. The ...

Leaving ED Without Being Seen Entails Increasing Risks Researchers call for long-term, consistent funding for primary, emergency, hospital, and long-term care. Medscape Medical News, January 09 ...

Tirzepatide is under clinical development by Eli Lilly and Co and currently in Pre-Registration for Obstructive Sleep Apnea. According to GlobalData ... Tirzepatide (Mounjaro, Persovance, Zepbound) is ...